{"id":"nai","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-15%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"4c197131-9ca8-6024-e063-6294a90aa9cb","title":"TREATONIC TONENAIL FUNGUS TREATONIC KIT. (25% UNDECYLENIC ACID AND TOLNAFTATE 1%) KIT [100 KARMA INC]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NAI works by binding to the norovirus capsid protein, preventing the virus from entering host cells and replicating. This leads to a reduction in viral load and alleviation of symptoms. NAI has been shown to be effective against various norovirus strains.","oneSentence":"NAI is an antiviral medication that inhibits the replication of the norovirus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:02:48.298Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of acute gastroenteritis caused by norovirus"}]},"trialDetails":[{"nctId":"NCT06123182","phase":"NA","title":"Guided Episodic Future Thinking to Increase Physical Activity Adherence and Promote Healthy Brain Aging","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2024-02-23","conditions":"Exercise Training, Aging","enrollment":160},{"nctId":"NCT07492875","phase":"PHASE3","title":"Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis","enrollment":10},{"nctId":"NCT07492888","phase":"PHASE2","title":"Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04-15","conditions":"Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis","enrollment":20},{"nctId":"NCT07488884","phase":"PHASE1","title":"Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-03-01","conditions":"Pancreatic Cancer Resectable, Pancreatic Cancer","enrollment":30},{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06753474","phase":"PHASE1","title":"A/Texas Flu Challenge","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-02-04","conditions":"Influenza","enrollment":50},{"nctId":"NCT06239220","phase":"PHASE2","title":"PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC","status":"RECRUITING","sponsor":"Glenn J. Hanna","startDate":"2024-02-16","conditions":"Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer","enrollment":25},{"nctId":"NCT06061809","phase":"PHASE2","title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2024-08-07","conditions":"Glioblastoma","enrollment":34},{"nctId":"NCT06217822","phase":"PHASE1","title":"First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-03-07","conditions":"Advanced Metastatic Castration-resistant Prostate Cancer, Prostate Specific Membrane Antigen (PSMA) Expression","enrollment":198},{"nctId":"NCT06474312","phase":"NA","title":"Reducing Suicide Ideation Among Young People","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pittsburgh","startDate":"2023-08-01","conditions":"Suicidal Ideation, Suicide, Attempted","enrollment":272},{"nctId":"NCT07209345","phase":"NA","title":"Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-10-15","conditions":"Post-craniotomy, Pain","enrollment":216},{"nctId":"NCT07123727","phase":"PHASE2","title":"A Study to Examine Anktiva for the Treatment of COVID-19.","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-09-04","conditions":"Long COVID, Long COVID Syndrome, Long Covid 19","enrollment":40},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06956547","phase":"","title":"Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy","status":"AVAILABLE","sponsor":"ImmunityBio, Inc.","startDate":"","conditions":"Lymphopenia","enrollment":""},{"nctId":"NCT05624359","phase":"NA","title":"Flurbiprofen Axetil as an Adjuvant to Pre-emptive Scalp Infiltration","status":"SUSPENDED","sponsor":"Beijing Tiantan Hospital","startDate":"2023-11-01","conditions":"Postoperative Pain","enrollment":216},{"nctId":"NCT03044587","phase":"PHASE2","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-24","conditions":"Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract","enrollment":93},{"nctId":"NCT03837977","phase":"PHASE2","title":"Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2018-11-13","conditions":"Oncology, Neuroendocrine Carcinoma","enrollment":58},{"nctId":"NCT05668962","phase":"PHASE2","title":"Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2023-03-01","conditions":"Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer","enrollment":30},{"nctId":"NCT05255666","phase":"PHASE2","title":"Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2023-07-31","conditions":"Triple Negative Breast Cancer, Brain Metastases","enrollment":""},{"nctId":"NCT04603989","phase":"PHASE1","title":"A Study of HNC042 in Healthy Chinese Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics","status":"COMPLETED","sponsor":"Guangzhou Henovcom Bioscience Co. Ltd.","startDate":"2020-08-01","conditions":"Influenza","enrollment":36},{"nctId":"NCT05008679","phase":"NA","title":"The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2021-02-25","conditions":"Heart Failure","enrollment":388},{"nctId":"NCT03684044","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-01-08","conditions":"Influenza","enrollment":363},{"nctId":"NCT04684498","phase":"PHASE4","title":"Open-label Study of Neuraminidase Inhibitor Treatment in STEMI Patients","status":"UNKNOWN","sponsor":"Tongji Hospital","startDate":"2020-03-01","conditions":"ST Elevation Myocardial Infarction, STEMI","enrollment":382},{"nctId":"NCT04297462","phase":"NA","title":"Different Regimens in Influenza Postexposure Chemoprophylaxis in Children","status":"UNKNOWN","sponsor":"Centre of Postgraduate Medical Education","startDate":"2016-11-17","conditions":"Influenza, Exposure, Prevention","enrollment":50},{"nctId":"NCT00803595","phase":"PHASE3","title":"A Multinational Phase III Study of CS-8958 (MARVEL)","status":"COMPLETED","sponsor":"Daiichi Sankyo Co., Ltd.","startDate":"2008-11","conditions":"Influenza, Human","enrollment":1002},{"nctId":"NCT01231620","phase":"PHASE3","title":"A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-01-15","conditions":"Influenza, Human","enrollment":626},{"nctId":"NCT01314963","phase":"NA","title":"Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-06","conditions":"Multiple Myeloma, Breast Cancer","enrollment":50},{"nctId":"NCT01527110","phase":"PHASE3","title":"A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-01","conditions":"Influenza, Human","enrollment":21},{"nctId":"NCT00334529","phase":"PHASE2","title":"Alternative Oseltamivir Dosing Strategies","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06-05","conditions":"Influenza","enrollment":48},{"nctId":"NCT00297050","phase":"PHASE1","title":"Safety and Dose Study of Peramivir for Influenza Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-02-23","conditions":"Influenza","enrollment":100},{"nctId":"NCT03111979","phase":"PHASE4","title":"The Effects of 4 Week β-alanine Supplementation on Knee Extensor Contractile and Force Properties in the Over 60s","status":"SUSPENDED","sponsor":"Nottingham Trent University","startDate":"2014-04","conditions":"Muscle Function","enrollment":24},{"nctId":"NCT01014988","phase":"PHASE2","title":"Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Influenza, Human","enrollment":202},{"nctId":"NCT02819505","phase":"PHASE4","title":"β-alanine Supplementation on Knee Extensor Contractile and Force Properties","status":"COMPLETED","sponsor":"Nottingham Trent University","startDate":"2014-12","conditions":"Muscle Function","enrollment":23},{"nctId":"NCT02665351","phase":"PHASE2, PHASE3","title":"Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2011-02","conditions":"Influenza","enrollment":16},{"nctId":"NCT00867139","phase":"PHASE1, PHASE2","title":"TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2009-03","conditions":"Influenza","enrollment":7},{"nctId":"NCT00640211","phase":"","title":"A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B","status":"WITHDRAWN","sponsor":"Kirby Institute","startDate":"","conditions":"Pandemic Influenza","enrollment":""},{"nctId":"NCT00799760","phase":"PHASE3","title":"Evaluation of Efficacity and Safety of Oseltamivir and Zanamivir","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-12","conditions":"Gastric Influenza","enrollment":541}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4661,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Interleukin-15","IL-15","Anktiva"],"phase":"marketed","status":"active","brandName":"NAI","genericName":"NAI","companyName":"Glenn J. Hanna","companyId":"glenn-j-hanna","modality":"Biologic","firstApprovalDate":"","aiSummary":"NAI is an antiviral medication that inhibits the replication of the norovirus. Used for Treatment of acute gastroenteritis caused by norovirus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}